Kura Oncology’s (KURA) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Thursday,RTT News reports. The brokerage currently has a $36.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on KURA. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Jefferies Financial Group decreased their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Bank of America reduced their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Price Performance

KURA opened at $7.65 on Thursday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $594.89 million, a P/E ratio of -3.24 and a beta of 0.78. The stock has a 50-day moving average price of $8.19 and a 200-day moving average price of $13.92. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. Equities analysts predict that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its holdings in shares of Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the period. SG Americas Securities LLC bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $436,000. Moody Aldrich Partners LLC grew its stake in Kura Oncology by 42.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after purchasing an additional 42,712 shares during the period. Harbor Capital Advisors Inc. raised its holdings in Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after purchasing an additional 2,076 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in Kura Oncology during the fourth quarter valued at $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.